Show description/summary:1) Reduction in Time to Treatment in Pre-hospital Telemedicine Evaluation and Thrombolysis2) What's Trending: gut microbiota regulate motor deficits and neuroinflammation in Parkinson diseaseOur podcast has changed to a two-segment format! Enjoy two in-depth interviews each week, starting with one featured article from the Neurology® family of journals followed by an interview on a trending topic or on a notable article from Neurology Today.This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 4, 2017 issue of Neurology. In the first segment, Dr. Andy Southerland interviews Dr. Shazam Hussain about his paper on time-to-treatment in pre-hospital telemedicine evaluation and thrombolysis. Then, for our “What's Trending” feature of the week, Dr. Alberto Espay talks with Dr. Sarkis Mazmanian about his paper on how gut microbiota regulate motor deficits and neuroinflammation in Parkinson Disease. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Hussain served on scientific advisory boards for pulsar neurovascular, penumbra, Inc., and Prolong Medical.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.For full disclosures, please contact Dr. Mazmanian directly at sarkis [at] caltech.edu.